CITALOPRAM HYDROBROMIDE

Post-LOE

Fosun Pharma

ANDAORALTABLET

Approved

Oct 2004

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

CITALOPRAM HYDROBROMIDE by Fosun Pharma is 12. Approved for major depressive disorder (mdd) in adults (). First approved in 2004.

Drug data last refreshed 19h ago

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of citalopram is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). 12.2 Pharmacodynamics In vitro and in…

Worked on CITALOPRAM HYDROBROMIDE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT01149980Phase 1Completed

Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions

Started Oct 2003

24 enrolled

Healthy

NCT01149967Phase 1Completed

Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions